Inozyme News and Activities

Inozyme is owned by Biomarin Pharmaceutical.

Biomarin Pharmaceutical is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Biomarin Pharmaceutical is a company listed under the stock ticker BMRN (US).

Biomarin Pharmaceutical has a direct presence in 5 countries.

Biomarin Pharmaceutical has 6 subsidiaries including Amicus Therapeutics, Amicus Therapeutics France and Amicus Therapeutics Germany.

They are in:

• Biotechnology86%
• Pharmaceuticals14%

Acquisition, funding and merger involving Biomarin Pharmaceutical.

• Biomarin Pharmaceutical has announced the acquisition of Inozyme  (posted on May 29 2025).

View the org chart displaying its 3 main executives

Most searched biographies at Inozyme

• Elizabeth Alessi, Vice President, Regulatory Affairs, Medical Writ...
• Jason Murray, Director, Sterile Drug Product
• Jitendra Gowda, Senior Manager, Clinical Data Management

Popular executive movements at Inozyme

• Matt Winton, Senior Vice President and Chief Operating Officer, has left the company  (posted on November 3 2025).
• Sanjay Subramanian, Senior Vice President and Chief Financial Officer, has left the company  (posted on November 3 2025).
• Stefan Riley, Senior Director, Investor Relations and Corporate Communications, has left the company  (posted on November 3 2025).

Click here to view some more movements at Inozyme

Popular executive movements at Biomarin Pharmaceutical

• Richard Meier, Chairman of the Board, will retire on Jun. 2, 2026  (posted on April 22 2026).
• Ian Clark who is Director, will become Chairman of the Board on Jun. 2, 2026  (posted on April 22 2026).
• Arpit Davé has joined the company as Chief Digital and Information Officer  (posted on January 13 2026).

Create your alert
to follow the executive moves at Inozyme.

Biomarin Pharmaceutical has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Inozyme

• Information About Inozyme Pharma’s Recent News - Inozyme Pharma
• Information About Inozyme Pharma’s Recent News - Inozyme Pharma
• Newsletters - Inozyme Pharma

Social media about Inozyme

• Inozyme on Wikipedia, Google News & Yahoo Finance
• Inozyme on LinkedIn, X (Twitter) & YouTube